Skip to main content

Cellis is founded on the broad and deep experience of the international team members we have brought together, providing strong expertise in scientific research, clinical development with a proven track record of identifying and developing commercially-successful innovative medicines.


Graduated in Veterinary Medicine from Warsaw University of Life Sciences (PL). In 2019, at age 38 she became a Full Professor. She visited several scientific centers: Sapienza University of Rome (IT), The Netherlands Cancer Institute (NL), Utrecht University (NL), Albert Einstein College of Medicine (USA), Yeshiva University (USA). Currently, she is a Head of the Department of Cancer Biology at Warsaw University of Life Sciences. She received multiple grants, fellowships, and awards. In 2020, she was short-listed finalist of the EU Prize for Woman Innovators.

Prof. Magdalena Krol, PhD

Chief Executive Officer, Co-founder
Immunologist with expertise in immune cell activation in cancer biology. In 2002, he was awarded with an Erasmus Scholarship to participate in a PhD program at the Netherlands Cancer Institute (NL), earning doctoral degree in 2007. After postdoctoral fellowship at the University Medical Center Utrecht (NL), he became an Assistant Professor in the Department of Immunology at Medical University of Warsaw (PL). Since 2021, he is also a Group Leader at Mossakowski Medical Research Institute, Polish Academy of Sciences (PL). He received several national research grants and two scholarships from the Polish Ministry of Education and Science.

Tomasz Rygiel, PhD

Chief Scientific Officer, Co-founder

Robert Aleksandrowicz, MD, MBA

Chief Business Officer

Przemyslaw Mencel

Chief Financial Officer

Lubomir Bodnar, PhD, MD

Chief Medical Officer
Dr. Marszałek obtained her PhD in Biophysics from the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences. She has several years of experience in drug development in both academia and biotech industry. She is an author of several scientific papers, honored with two international scholarships and several national, and international awards. At Cellis, she oversees biochemical research team and co-builds new strategies for protein-drug design, development, and manufacturing.

Ilona Marszalek, PhD

Head of Medicinal Chemistry
Dr. Gabrusiewicz spent over six years at MD Anderson Cancer Center at Brain Tumor Center (Houston, USA) exploring glioblastoma microenvironment and elucidating the mechanisms of tumor-mediated immune suppression. He has many years of experience in cell therapy development for solid tumors (CAR-T, TCR-T, gamma/delta-T and CAR-monocytes/macrophages). Previously he worked at Kiromic Biopharma Inc., Ziopharm Oncology Inc. (currently Alaunos Therapeutics), Carisma Therapeutics Inc. and Bellicum Pharmaceuticals Inc. (USA).

Konrad Gabrusiewicz, PhD

Director of Science Liaisons
Dr. Taciak obtained his PhD from Warsaw University of Life Sciences in 2019. He was a primary recipient of a grant from the National Science Centre to study an impact of macrophages on Wnt signaling pathway in cancer cells. During his PhD program he spent several months at Bilkent University, Turkey and in the laboratory of prof. Jeffrey Pollard at the University of Edinburgh, UK. Currently, he leads a team of young scientists at R&D site testing killing abilities of MDC in variety of cancer types.

Bartlomiej Taciak, PhD

R&D Group Leader

Michalina Kappeler

Legal Counsel

Advisors and Cooperators

Group Leader in the Department of Biochemical Sciences at Sapienza University of Rome. During his scientific career he worked at the following scientific centers: Université de Luminy II Marseille (FR), Albert Einstein College of Medicine (USA), National Research Council CNR (IT). He is a co-founder of number of companies, majority of them have been sold or acquired. Currently, he serves as a consultant for a number of biotech companies.

Prof. Alberto Boffi, PhD

Dr. Simpson has 15 years of experience in biologics development and commercialization with Cobra Biologics, Eden Biodesign and Actavis, and supported IP Group to develop Glythera’s business strategy and fundraising activities. Currently he is a CEO at Iksuda Therapeutics and non-executive Director at Leaf Expression Systems.

David Simpson, PhD

Dr. Weiss has many years of clinical and scientific experience in brain tumors. Currently, he is Senior Physician and Researcher at University Hospital of Zurich (Switzerland). He works at Neuroscience Center Zurich in a team of Prof. Michael Weller where Cellis runs glioblastoma project.

Tobias Weiss, PhD, MD

Anthony Brown, PhD

Prof. Magdalena Letowska, PhD, MD

Prof. Robert Klopfleisch, PhD, MD